News
Fintpla is approved by MHLW to treatseizures in Japan associated with Dravet syndrome
UCB, a global biopharmaceutical company, announced that Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older
Fintpla will be available at all Japanese hospitals and pharmacies. Fenfluramine will be marketed by Nippon Shinyaku Co., Ltd. based on the exclusive sales agreement signed in 2019 between Zogenix Inc., (acquired by UCB in 2022) and Nippon Shinyaku Co., Ltd. UCB is now the Marketing Authorization holder.
Condition: Dravet syndrome
Type: drug